MedCity News May 11, 2021
Ginkgo Bioworks, a company whose cell engineering work can be found in products ranging from food ingredients to vaccines, is going public in a SPAC deal that values it at $15 billion. The merger will infuse it with $2.5 billion in capital to invest in its platform technology.
Ginkgo Bioworks, a synthetic biology company with technology that programs cells in the same way that coders program computers, is going public in a merger deal that values the firm at $15 billion.
Boston-based Ginkgo announced Tuesday that it is combining with Soaring Eagle Acquisition Corp, a special purpose acquisition company (SPAC). The hefty valuation that the deal attaches to Ginkgo reflects the growing demand for bioengineered products and the biotech’s place...
Today's Sponsors
Today's Sponsor